Global Cervical Cancer Diagnostics Market Report 2020-2030: COVID-19 Growth and Changes Expected - ResearchAndMarkets.com - Tullahoma News and Guardian
Global Cervical Cancer Diagnostics Market Report 2020-2030: COVID-19 Growth and Changes Expected - ResearchAndMarkets.com - Tullahoma News and Guardian |
- Global Cervical Cancer Diagnostics Market Report 2020-2030: COVID-19 Growth and Changes Expected - ResearchAndMarkets.com - Tullahoma News and Guardian
- Pap smear tests: At what age and how often? - India New England
- A free 24-hour COVID test is available after a private Billings lab developed one from scratch - KTVQ Billings News
| Posted: 30 Dec 2020 03:16 AM PST  DUBLIN--(BUSINESS WIRE)--Dec 30, 2020-- Cervical Cancer Diagnostics Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global cervical cancer diagnostics market. Major players in the cervical cancer diagnostics market are Abbott Laboratories, Becton, Dickinson and Co., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Hologic Inc., QIAGEN NV, Quest Diagnostics Inc., Siemens Healthineers AG, Zilico, and Guided Therapeutics. The global cervical cancer diagnostics market is expected to decline from $8.02 billion in 2019 to $7.23 billion in 2020 at a compound annual growth rate (CAGR) of -9.87%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, especially postponement of non-emergency procedures. The market is then expected to recover and reach $8.62 billion in 2023 at a CAGR of 6.04%. The cervical cancer diagnostics market consists of sales of cervical cancer diagnostic devices and related services by entities (organizations, sole traders and partnerships) that produce cervical cancer diagnostics devices. Cervical cancer is a type of cancer that occurs in cells of the cervix. These devices are used for the diagnosis of cervical cancer. North America was the largest region in the cervical cancer diagnostics market in 2019. In November 2018, QIAGEN, a German-based leading supplier of specimen and assay systems for diagnostic techniques, applied testing, academic and pharmaceutical research, collaborated with Self-screen BV and released the QIAscreen HPV PCR Test, a CE-IVD molecular diagnostic test for the detection of 15 recognized high-risk human papillomavirus (HPV) genotypes, which is considered to be the cause of cervical cancer. Self-screen BV is a VU University Medical Centre's spinoff company based in the Netherlands. The rising adoption of cervical cancer diagnostic tests for the early detection of cervical cancer is expected to drive the market for cervical cancer diagnostics. Increasing awareness among women about cervical cancer along with the emphasis by worldwide cancer organizations and governments on early testing for detecting cervical cancer and preventing it contributes to the growth of the market. The increased adoption of HPV home testing kits is expected to be the new trend in the market. The home-based HPV testing kits help women in collecting samples and getting the results conveniently on their own without going to the lab for screening. Therefore, companies are focusing on providing convenience to patients. The increased use of HPV vaccination is anticipated to hinder the cervical cancer diagnostics market. According to the World Health Organization, the 2 HPV types (16 and 18) cause 70% of cervical cancers and pre-cancerous cervical lesions, thereby giving human papillomavirus (HPV) vaccine is effectively reducing the numbers of cervical pre-cancerous lesions that may develop into cervical cancers. The study published in Cancer Epidemiology, Biomarkers & Prevention, in February 2019 supported the information from the Centers for Disease Control and Prevention (CDC) that states that among women who had been vaccinated, the share of precancers caused by HPV 16 and 18 dropped from 55.2% to 33.3% whereas, in unvaccinated women, the proportion dropped from 51% to 47.3%. The HPV vaccine is recommended by the Centers for Disease Control and Prevention (CDC) for all the kids and adults between the ages of 9 to 26. Therefore, the increased use of HPV vaccination is predicted to hinder the cervical cancer diagnostics market. Key Topics Covered: 1. Executive Summary 2. Cervical Cancer Diagnostics Market Characteristics 3. Cervical Cancer Diagnostics Market Size And Growth 3.1. Global Cervical Cancer Diagnostics Historic Market, 2015 - 2019, $ Billion 3.1.1. Drivers Of The Market 3.1.2. Restraints On The Market 3.2. Global Cervical Cancer Diagnostics Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion 3.2.1. Drivers Of The Market 3.2.2. Restraints On the Market 4. Cervical Cancer Diagnostics Market Segmentation 4.1. Global Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
4.2. Global Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5. Cervical Cancer Diagnostics Market Regional And Country Analysis 5.1. Global Cervical Cancer Diagnostics Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion 5.2. Global Cervical Cancer Diagnostics Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion Companies Mentioned
Laura Wood, Senior Press Manager For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 INDUSTRY KEYWORD: HEALTH ONCOLOGY MEDICAL DEVICES SOURCE: Research and Markets Copyright Business Wire 2020. PUB: 12/30/2020 06:16 AM/DISC: 12/30/2020 06:16 AM  |
| Pap smear tests: At what age and how often? - India New England Posted: 07 Dec 2020 12:00 AM PST  New Delhi– Being the second most common cancer in women between the age group of 15 and 44 years of age, the awareness towards cervical cancer and its screening is miniscule in our country. Cervical cancer is a completely preventable disease because of its well defined, long pre-malignant phase and it can be detected easily by regular screening tests and follow up. Unfortunately, the females in India are unaware about the screening process for the cervical cancer care. With the vaccination, screening and treatment, the World Health Organization (WHO) has recently aimed to reduce more than 40 percent of new cases and 5 million related deaths of cervical cancer by 2050. Q. What's a pap smear test? A: Dr Sandeep Chadha Consultant Obstetrician & Gynecologist, Motherhood Hospital, Noida explains: "It's crucial that we should also learn about Pap smear test. It's a screening test used to detect potentially pre-cancerous and cancerous processes in the endocervical canal. The doctor takes out a cluster of cells from a person's cervix using a spatula-like instrument to look for changes in the cervix's cells. A pap smear helps in diagnosing cellular changes resulting from cancer, precancer, human papillomavirus (HPV), inflammation, or an infection." Q. At what age one can go for Pap smear? A. According to the Centers for Disease Control and Prevention (CDC) recommend, all women who fall between the age group of 21 and 65 years should get their Pap smears tests at regular interval, Dr Chadha says. "However, the National Institutes of Health (NIH) recommend that girls below 21-year-old should be refrained from pap smears. At the same time, they also suggest that women over 65-year-old shouldn't get a Pap smear except under certain circumstances, such as abnormal results or increased risk factors for cancer." However, both menopausal and postmenopausal, should continue to have Pap or HPV tests. Women who have had a total hysterectomy for a noncancerous condition and have not had a previous history of precancerous Pap tests may be able to stop Pap screening depending on their medical history and risk of contracting human papilloma virus (HPV), he adds. One should not forget that testing is the best tool to detect pre-cancerous conditions that may lead to cervical cancer. Cervical cancer can be cured if detected on time. Q. How often one should go for pap smear based on age? A. The expert lists down the following recommended testing schedules based on a person's age: – From 21-29 years The ideal age for having Pap smear is 21-year-old. If the result is negative then the next test would be done after the gap of three years. – From 30-65 years In this age, the person can either have a Pap test, or a combined Pap and HPV test after consulting with the doctor. In case of single Pap test, then the doctor would ask to come after three years if the tests are normal. When the person opt for the combined test, and both results are normal, the doctor would ask to wait for 5 years for the next screening test. If a person is having periods at the time of their scheduled appointment, they should check with their clinician whether they should go ahead with the test. In most of the cases, the test happens if you're menstruating. Doctors can suggest a person to avoid only the following before a Pap smear: – Having sex – Douching the vagina – Using tampons or vaginal lubrication – Vaginal creams, suppositories, or medications – Using birth control foam, cream, or jelly (IANS)  |
| Posted: 30 Dec 2020 07:58 AM PST  BILLINGS — Getting a COVID-19 test result can take up to seven days in Yellowstone County, but a private Billings practice has that length of time beat – and they want the public to know about it. At Yellowstone Pathology Institute they've found a way to offer the public a COVID-19 test that's ready in just 24 hours, reversing the frustration felt by many when it comes to waiting for results. And the test is free with the help of CARES Act dollars. In Yellowstone County, positive case numbers have dipped slightly but the threat of a new mutated strain has been seen across the globe. "You know I don't think that we're quite done with this epidemic yet," said Dr. Angela Durden. She along with her colleagues have been monitoring the virus closely since its arrival. Yellowstone Pathology Institute is comprised of 8 total pathologists performing diagnoses based on technical results. The lab performs clinical pathology services including those associated with surgical pathology, cancer diagnostics and testing related to women's health such as pap smears and HPV screening, among other things. The lab employs 30 people. "We are experienced in laboratory testing that is our schtick, if you will," said Durden. "We said, why not? Why couldn't we try to do this right here locally." Durden is talking about testing for COVID-19. That's because months ago, supply shortages impacted medical laboratories everywhere. Shortages were seen in sample collection materials, testing kits and even staffing. Durden says the impact meant a "prolonged turnaround time" for COVID-19 results which ultimately extended quarantine times for people needing to get back to work, school and even those needing medical procedures. "And that's had a big impact on a lot of people," said Dr. Michael Brown. "People that need to travel people that want to go see their families." And the turnaround time is still a headache for many, most waiting as much as seven days in Yellowstone County to get their test results back from the county health department's community testing site. Meanwhile though at Yellowstone Pathology as many as 400 COVID-19 samples are coming in for testing and, in turn, going back out within just 24 hours. Brown says the lab could even handle a capacity of more. But how is it possible for this private practice to test for COVID? As Brown explains they had to build their own test kit from scratch and its not only effective it is considered the "gold standard" when it comes to testing. "Our test is a PCR based test so we're looking for the RNA In the virus," said Brown. Those with Yellowstone Pathologists say their practice of board-certified pathologists specialize in laboratory testing and the diagnosis of disease from tissue samples. "Our skill set and the independent nature of our practice have uniquely positioned us to act quickly in response to the testing shortage," said Durden. The materials for the test were sourced from manufacturers across the globe. "It has the highest performance characteristics that you see for tests on the market," said Brown. The practice also invested in additional robotic technology to create their own high-throughput test. "We rigorously validated our test to ensure its quality and performance and have submitted a request to the FDA for Emergency Use Authorization," said Durden. And they do it because there's a need. Waiting for a test result can be crippling, according to Durden. "You know it's easy to send your test off and then, you know, suddenly you're waiting a week because once your sample arrives in some lab in North Carolina they pretty much tell you get in line," she said. The mission is to provide some relief to state and local jurisdictions and eliminate that bottleneck, which leads to residents staying healthy in this global pandemic and moreover getting back to work in a struggling economy. "I think this test was born partially out of frustration because, you know, the lack of testing impacted us as well," said Durden. "I mean we also have a workforce in our laboratory and we also have people that we have to look out for." At first the samples were coming from referrals from area doctor's offices and other practices, but those with Yellowstone Pathology want the public to know anyone can get tested through their lab. Durden and Brown also say their test is not to be confused with several antigen based rapid COVID tests available online. Those tests can yield false negative and false positive results, said Durden. And coming at the end of January, Yellowstone Pathology plans to open a COVID-19 test collection center in the Yellowstone Medical Center where anyone can drop in, have their sample collected and get their results in hours.  |
| You are subscribed to email updates from "hpv test" - Google News. To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google, 1600 Amphitheatre Parkway, Mountain View, CA 94043, United States | |
Comments
Post a Comment